About Profusa | Mission-Driven Team | NASDAQ: PFSA
Profusa / About

Our Mission: Personalized Healthcare
Powered by Real-Time Biochemistry

Profusa was founded on a simple but transformative idea: that continuous, real-time measurement of the body's own chemistry — delivered from inside the tissue — would unlock a new era of personalized, preventive, and precision medicine. More than 10 years and $100M+ later, we are delivering on that promise.

Company

Built on Deep Science.
Driven by Clinical Need.

Profusa, Inc. (NASDAQ: PFSA) is a San Francisco-based medical device and digital health company pioneering injectable hydrogel biosensors and AI-driven health management platforms. The company's Lumee™ platform is the culmination of a decade of research, more than $100 million in investment, and $30 million in non-dilutive funding from DARPA and the National Institutes of Health.

Our platform addresses two of the most significant unmet needs in modern medicine: real-time tissue oxygen monitoring for vascular surgery patients, and long-duration continuous glucose monitoring accessible to the full spectrum of diabetes and prediabetes patients. With 85 global patents granted or pending, Profusa is moving from deep science to commercial reality.

Mission-Driven Executive Leadership
Ben Hwang, Ph.D.
Chairman & CEO

Ben brings deep experience in life sciences commercialization — from undergraduate research at Caltech in the lab of Leroy Hood (where the automated DNA sequencer was developed), to bringing cutting-edge tools to market at Life Technologies Corp. (acquired by Thermo Fisher Scientific). Ben has seen first-hand how science transforms medicine.

Bill McMillan
Co-Founder, CSO & Head of Research

Bill was the initial driving force behind Profusa — building the company roadmap, enlisting top talent, and securing seed funding. A co-inventor of Profusa's biologically integrated sensor and optical reader, Bill is a biotech pioneer with more than 30 years in next-generation diagnostic and medical device development, including 20 years as an entrepreneur.

Fred Knechtel
Chief Financial Officer

Fred has led finance and operations from startups to multi-billion dollar public companies across life sciences, automotive, consumer products, and aerospace — including Northrop Grumman, Stanley Black & Decker, DuPont, Remy International, Sims Metal Management, and GENEWIZ (Azenta). He has guided organizations through growth, restructuring, M&A, and IPOs.

Kerstin Rebrin, M.D., Ph.D.
VP Medical Affairs & Clinical Development

Dr. Rebrin is a physician-scientist with deep clinical and research experience in diabetes and metabolic disease. She is known for pioneering work in artificial pancreas research, introducing continuous glucose sensing and therapy algorithms for various routes of insulin delivery. She develops and executes Profusa's medical and clinical strategy.

Aude Sordet
General Manager, Europe

Aude brings extensive international experience in commercial strategy, marketing, and business leadership across Europe and Asia — with senior roles at Bayer, M8 Pharmaceuticals, and GC Aesthetics. She combines medical insight with strategic vision to drive Profusa's European commercial launch and regional partnerships.

Sean Givens
Head of Government Business

Sean brings 20 years of experience in government accounting and contracting, plus operations experience across consumer electronics, medical devices, and drug development. Previously Co-Founder and COO of MIODx (focused on immune repertoire). He oversees Profusa's DARPA and NIH government contract relationships.



Validated by the Organizations That Matter Most
🏛
Government Funding
DARPA: $30M+ non-dilutive grants
National Institutes of Health (NIH)
🤝
Technology Partners
NVIDIA — AI technology backbone
AngioPro — EU distribution
Dismeval, S.L. — Spain distribution
💼
Financial Backers
Family Offices · Venture Capital
PIPE Investors · Equity Line Of Credit